REGINfo: GALAPAGOS - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$GALAPAGOS: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2020.09.18 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos increases share capital through subscription right exercises - HTML (w)

2020.09.18 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten - HTML (w)

2020.09.11 | 04:30 | Permanent Information Releases / General Company News

puce Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients - HTML (w)

2020.09.11 | 04:30 | Permanent Information Releases / General Company News

puce Primair eindpunt bereikt met ziritaxestat in NOVESA-studie bij patiënten met systemische sclerose - HTML (w)

2020.08.26 | 07:30 | Permanent Information Releases / General Company News

puce Galapagos to present new insights in IPF and related clinical developments at the European Respiratory Society Congress - HTML (w)

2020.08.26 | 07:30 | Permanent Information Releases / General Company News

puce Galapagos presenteert nieuwe inzichten in IPF en gerelateerde klinische ontwikkelingen op het European Respiratory Society Congress - HTML (w)

2020.08.19 | 01:25 | Permanent Information Releases / General Company News

puce Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis - HTML (w)

2020.08.19 | 01:25 | Permanent Information Releases / General Company News

puce Galapagos kondigt aan dat Gilead een Complete Response Letter voor filgotinib heeft ontvangen voor de behandeling van matige tot ernstige actieve reumatoïde artritis - HTML (w)

2020.08.12 | 22:01 | Permanent Information Releases / General Company News

puce Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease - HTML (w)

2020.08.12 | 22:01 | Permanent Information Releases / General Company News

puce Scipher Medicine en Galapagos ondertekenen samenwerkingsovereenkomst voor inflammatoire darmziekten - HTML (w)

2020.08.06 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos reports solid H1 2020 progress - HTML (w)

2020.08.06 | 22:01 | Permanent Information Releases / General Company News

puce Galapagos rapporteert sterke voortgang in H1 2020 - HTML (w)

2020.07.24 | 14:14 | Permanent Information Releases / General Company News

puce GILEAD AND GALAPAGOS ANNOUNCE POSITIVE EUROPEAN CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS - HTML (w)

2020.07.24 | 14:14 | Permanent Information Releases / General Company News

puce GILEAD EN GALAPAGOS KONDIGEN POSITIEVE EUROPESE CHMP OPINIE AAN VOOR JYSELECA® (FILGOTINIB) VOOR DE BEHANDELING VAN VOLWASSENEN MET MATIGE TOT ERNSTIGE REUMATOïDE ARTRITIS - HTML (w)

2020.06.05 | 22:01 | Permanent Information Releases / General Company News

puce NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 258